The Patent Finder

Karyopharm Therapeutics Inc.

57 patents currently held · Updated Nov 22, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

1
Ending by 2030
Nov 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Jan 2 to 30, 2027 · next Jan 2
  • 1 fee due Feb 4, 2027
    The maintenance fee for Nuclear Transport Modulators and Uses Thereof (US 9,096,543) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
  • 4 fees due Mar 3 to 12, 2027 · next Mar 3
  • 1 fee due Apr 17, 2027
    The maintenance fee for Hydrazide Containing Nuclear Transport Modulators and Uses Thereof (US 11,787,771) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
  • 1 fee due May 7, 2027
    The maintenance fee for Polymorphs of Selinexor (US 11,807,629) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
  • 2 fees due Jun 8 to 30, 2027 · next Jun 8
  • 2 fees due Jul 7 to 28, 2027 · next Jul 7
  • 1 fee due Aug 23, 2027
    The maintenance fee for Nuclear Transport Modulators and Uses Thereof (US 9,266,843) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
  • 2 fees due Oct 2 to 14, 2027 · next Oct 2

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 24, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,921,315A Method of Increasing Survival of a Human Subject Having Exposure to an Acute Exposure to Non-Therapeutic Whole Body Ionization by Administering a Therapeutically Effective Dose of IL-12
In force
 · High confidence
In forceHigh confidence
US 8,735,342Method for Treating Brain Cancer Using a Novel Tumor Suppressor Gene and Secreted Factor
In force
 · High confidence
In forceHigh confidence
US 8,513,230Nuclear Transport Modulators and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,550,757Nuclear Transport Modulators and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,878,012IL-12 Formulations for Enhancing Hematopoiesis
In force
 · High confidence
In forceHigh confidence
US 8,962,317Uses of IL-12 and the IL-12 Receptor Positive Cell in Tissue Repair and Regeneration
In force
 · High confidence
In forceHigh confidence
US 9,206,158Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 9,714,226Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,173,987Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,544,108Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
In force
 · High confidence
In forceHigh confidence
10 of 57 patents shown.
Pro members see all 57.
Pro members: see all 57 patents
Also on record, not counted in the 57: 1 patent in force now held by others · 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 8 abandoned

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited